reports
Eversource Energy: 1 director
A director at Eversource Energy sold 12,339 shares at 74.035USD and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results an...
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027 Enrollment Completed in VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Bo...
Moody's Ratings assigns Baa3 rating to Eversource's junior subordinate...
Moody's Ratings (Moody's) today assigned Baa3 ratings to two tranches of Eversource Energy's (Eversource) Junior Subordinated Notes (JSNs) due 2056. The rating outlook is negative. RATINGS RATIONALE The Baa3 rating assigned to Eversource's JSNs reflects the security's relative position in Ev...
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in the Wells Fargo Executive Biotech Summit, TD Cowen 46th Annual Health Care Conference, and UBS Biotech Summit. The details of the meetings are as follows: Wells Fargo Executive Biotech Summit Format: One-o...
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Res...
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026 before market open. The company will host a teleconference in conjunction with its financial results pre...
Entergy Corp: 2 directors
Two Directors at Entergy Corp sold/sold after exercising options 38,666 shares at between 104.022USD and 105.120USD. The significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the ...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Upgrade Staples to Overweight; Downgrading Services We maintain our near-term bullish outlook on the S&P 500 (SPX) and Russell 2000 (IWM), which has remained in place since 4/22/25, aside from one week (11/19/25-11/25/25) when we went to neutral. We will stay near-term bullish as long as crucial support levels of 6780-6824 on SPX and $255-$257 on IWM continue to hold; every minor dip below these levels has been for no longer than a day, before buyers have stepped-in. We continue to see more det...
WEC WEC ENERGY GROUP INC
SRE SEMPRA ENERGY
REG REGENCY CENTERS CORPORATION
NEE NEXTERA ENERGY INC.
EXC EXELON CORPORATION
ETR ENTERGY CORPORATION
ED CONSOLIDATED EDISON INC.
DUK DUKE ENERGY CORPORATION
D DOMINION ENERGY INC
CVE CENOVUS ENERGY INC.
CNP CENTERPOINT ENERGY INC.
SLI STA. LUCIA LAND
CNQ. CANADIAN NATURAL RESOURCES LIMITED
RENN RENN GLOBAL ENTREPRENEURS FUND
ETS ELITE EXPRESS HOLDING INC
Merck & Co Inc: 1 director
A director at Merck & Co Inc sold 10,000 shares at 121.456USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VA...
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027 OPUS-1, VAX-31 Adult Phase 3 Noninferiority Trial, Continues to Enroll Subjects, with Topline Data Expected in Fourth Quarter of 2026 Vaxcyte’s VAX-31 Phase 3 Adult Clinical Program – Finalized in Consultation and Alignment with U.S. Food and Drug Administrati...
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results ...
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business update after market close on February 24, 2026. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT. To participate in the conference call, please dial 800-445-7795 (domestic) or ...
Kimberly Clark Corp: 1 director
A director at Kimberly Clark Corp bought 10,000 shares at 104.147USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
- Jonathan Moreland
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
TCBI TEXAS CAPITAL BANCSHARES INC.
SXI STANDEX INTERNATIONAL CORPORATION
PAYX PAYCHEX INC.
NBTB NBT BANCORP INC.
MNRO MONRO INC
LXRX LEXICON PHARMACEUTICALS INC.
LMAT LEMAITRE VASCULAR INC.
HUN HUNTSMAN CORPORATION
GME GAMESTOP CORP. CLASS A
FFIN FIRST FINANCIAL BANKSHARES INC
CR CRANE CO.
GAM GENERAL AMERICAN INVESTORS CO. INC.
ENPH ENPHASE ENERGY INC.
PCF PUTNAM HIGH INCOME SECURITIES FUND
AGYS AGILYSYS INC.
TYIA JOHNSON CONTROLS INTERNATIONAL PLC
LW LAMB WESTON HOLDINGS INC.
HWKN HAWKINS INC.
WDFC WD-40 COMPANY
HYT BLACKROCK CORPORATE HIGH YIELD FUND VI
CVCO CAVCO INDUSTRIES INC.
CRVS CORVUS PHARMACEUTICALS
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
ABT ABBOTT LABORATORIES
MVBF MVB FINANCIAL CORP
THM INTERNATIONAL TOWER HILL MINES LTD
NWFL NORWOOD FINANCIAL CORP.
ZIVO ZIVO BIOSCIENCE
SONO INC.
ANIX SONOS
ETON ANIXA BIOSCIENCES
AMTB ETON PHARMACEUTICALS
JYNT AMERANT BANCORP (A)
ALLY THE JOINT
CMTV GMAC LLC
ALXO COMMUNITY BANCORP INC. VT
AZYO ALX ONCOLOGY HOLDINGS
LUMN AZIYO BIOLOGICS
BST LUMEN TECHNOLOGIES INC.
LSF BLACKROCK SCIENCE AND TECHNOLOGY TRUST
VANI LAIRD SUPERFOOD INC
BOF VIVANI MEDICAL INC
WS WI BRANCHOUT FOOD INC.
MXF WORTHINGTON STEEL
GDV THE MEXICO FUND
PMN INC.
IP THE GABELLI DIVIDEND & INCOME TRUST
CVM PROMIS NEUROSCIENCES INC.
FEAM INTER PHARMA PUBLIC COMPANY LIMITED
BDSX CEL-SCI CORPORATION
MIGI 5E ADVANCED MATERIALS INC.
BIODESIX INC
MAWSON INFRASTRUCTURE GROUP INC
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit in New York on Thursday, February 12, 2026 at 1:30 p.m. ET / 10:30 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at . A replay of the webcast will be available for approximately 30 days foll...
- Jonathan Moreland
SXI STANDEX INTERNATIONAL CORPORATION
LXRX LEXICON PHARMACEUTICALS INC.
FFIN FIRST FINANCIAL BANKSHARES INC
PCF PUTNAM HIGH INCOME SECURITIES FUND
CVCO CAVCO INDUSTRIES INC.
RRBI RED RIVER BANCSHARES
ALXO ALX ONCOLOGY HOLDINGS
FRST PRIMIS FINANCIAL CORP
WRB W.R. BERKLEY CORPORATION
GAM GENERAL DE ALQUILER DE MAQUINARIA
FIG FIGMA INC.
FEAM 5E ADVANCED MATERIALS INC.
- Michael Piccolo
Daily Recap: VRNS, CYBR/PANW, LYV, WBS/SAN, SLAB/TXN, SITM, RSVR, GRAB...
CyberArk Software Ltd. (CYBR - $406.67) and Palo Alto Networks, Inc. (PANW - $166.24)Target Reports Earnings; Pending Acquisition On-Track to Close Before End of April; Acquirer Stock Seems Oversold. CYBR announced record 4Q and FY'2025 financial results featuring record net new ARR of $99 million
Vaxcyte Announces Closing of $632.5 Million Public Offering Including ...
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of common stock at a public offering price of $50.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,650,000 additional shares of common stock at the public offering pr...
ALX Oncology Announces Pricing of Underwritten Offering
ALX Oncology Announces Pricing of Underwritten Offering SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced the pricing of an underwritten offering of common stock and pre-funded warrants. ALX Oncology is selling 76,979,112 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,574,120 shares of common stock in the offeri...
New Data Demonstrate CD47 Expression Level Helps Predict Response to A...
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer - Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – - Full data set submitted for presentation at an upcoming scientific conference - SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-st...
Vaxcyte Announces Pricing of $550 Million Public Offering
Vaxcyte Announces Pricing of $550 Million Public Offering SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of common stock. Vaxcyte is selling 11,000,000 shares of common stock in the offering at a public offering price of $50.00 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be $550 million, before deducting underwriting discounts and commissions and other offering expenses. All shares of common stock to be s...
Vaxcyte Announces Commencement of Proposed Public Offering of Common S...
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering of $500,000,000 of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 of shares of its common stoc...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.